Breast Cancer Market (By Therapy: Targeted Therapy, Hormonal Therapy, Surgery and radiation therapy, Biologic therapy; By Cancer Type: Hormone Receptor, HER2+; By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023-2032
The global breast cancer market size was estimated at USD 28.8 billion in 2022 and is projected to hit around USD 73.68 billion by 2032 with a registered CAGR of 9.9% during the forecast period 2023 to 2032.
Access our Healthcare Data Intelligence Tool with 10000+ Database, Visit: Towards Healthcare
Breast cancer is the most commonly occurring disorder among the population majorly seen in females with rising disorder. Breast cancer is mostly developed in the tissues of the breast. Symptoms of breast cancer are the formation of lumps in the breast, size and shape difference of the breast, fluid coming out of the nipple, and irritating, scaly, red patches on the skin. It is a disorder that spreads the disease with increasing symptoms such as pain in the bones swelling of lymph nodes, breathing problems, and many more.
Breast cancer development takes place with the presence of genes like Human Epidermal growth factor receptor 2 (HER2). Stimulation of cancer in the body with the presence of this protein extends the proliferation of the cells. Positive HER2 receptor patients having the most aggression in breast cancer than other types of breast cancer. Numerous treatments are available which are used to treat and eradicate the tumor and increase the target on HER2. Which enlarges the market of Breast cancer with an increasing number of patients every year with an increase in the recovery rate of breast cancer.
Enhance research and development with increased new technologies and therapies developed in breast cancer which is prominently contributing to enhancing the market growth with increased demands from the medical sector for treating the patients with new treatments and medications. Government support with increasing providence for new developments in medications and increased efficiency and efficacy of the treatment and integration of newly developed medications in the medical sector.
The impact of covid-19 on the breast cancer market led to a lengthening of the treatment increased time span between treatments due to the widespread coronavirus and decreased rate of patients visiting the hospital with a reduced market of breast cancer. The post-pandemic situation with an increase in the market with significant development of medications and treatment of cancer with increasing the rate of breast cancer every year and enhanced demands from the customer and medical sector for the medication which helps to grow the breast cancer market.
Increasing prevalence of breast cancer in females every with increased growth of the breast cancer market with the increased number of medications. Improved methods for diagnosis of breast cancer with developed technologies. Increasing developed technologies in breast cancer with increased efficiency, accuracy, efficacy, reliability, and speed of the results with increased performance of detection of the disorder.
Enhanced features developed for detection of the cancer within less period of time. Cancer is detected at an early stage which helps the patients for faster recovery, the cancerous cell is prevented from spreading to other parts of the body and are treated with the new medications available on the market. Increased screening and imaging of the tumor boost the market for breast cancer.
Increased in research and development with an increased number of treatments introduced by the key market players in the breast market and increase funding from the key market players for the development of the medications and treatment and increase in research for diagnosis of the disorder with increased efficacy and within less period of time.
Increased support from the government for the integration of new treatments and medication in the health care sector with an increasing number of breast cancer among individuals due to reduced exercise, reduced obesity, increased intake of alcohol, hormone problem, menopause, family history of cancer enlarges market of breast cancer to a larger extend. Enhance benefits from the government with an increased number of policies developed such as reimbursement policies so that common people can take benefit of the treatment which are high in cost. This helps for the expansion of the market in breast cancer with new policies and cost effectivity help to increase the breast cancer market size.
The outbreak of Covid-19 with a reduced market of breast cancer reduced patients visits to the hospitals increased the gap between treatment with increased rules and norms imposed by the government due to the widespread coronavirus and an increase in research vaccine on coronavirus came up with an antimalarial drug that is hydroxychloroquine. Which is also effective in treating coronavirus and helps to encourage the market growth of breast cancer with the increasing prevalence of disorder and enhanced demands fuels the breast cancer market value.
Report Coverage | Details |
Market Size in 2023 | USD 31.51 Billion |
Market Size by 2032 | USD 73.68 Billion |
Growth Rate from 2023 to 2032 | CAGR of 9.9% |
Largest Market | North America |
Second Largest Market | Asia Pacific |
Base Year | 2022 |
Forecast Period | 2023 to 2032 |
Segments Covered |
|
Regions Covered |
|
Key Market Drivers
Key Market Challenges
Key Market Opportunities
On the basis of therapy, the market of breast cancer with more experienced professionals in therapies involved treatment with advanced developed therapies involved for treating breast cancer with increased demands from the market with rising disorder among the population. Increased research and technology in breast cancer medication with an improved number of treatments available help to grow the market rate share.
Targeted therapy involved in the breast market is the largest market with increased utilization of the therapy due to increased output and enhanced performance with new launches involved in the medications helping to accelerate the market of breast cancer. Targeted therapy drugs are such as Kadcyla, Afinitor, Lynparza, and Zortress. Immunotherapy involved also with a higher market share in the breast market with new regulatory approvals.
On the basis of cancer type analysis, the market of breast cancer is to extend the market share with the largest rate in the hormone receptor during the forecast period with an increasing number of cases of breast cancer every year with developed treatment with new innovative technologies to treat the disorder. Hormone receptor HER2 declined the market share but new launches in treating breast cancer may enhance the market to grow during the forecast period with an increased CAGR rate of the breast cancer market.
On the basis of distribution channels, hospital pharmacies with the highest market share developed their own pharmacies in the hospital. Due to the increased dependence of the patients on the medications required for chemotherapy. Increased demands from patients for various medications and enhanced availability of the medication in hospital pharmacies help to support the growth of the breast cancer market during the forecast period.
Online pharmacies with the largest market share due to increased software development in the hospital and increased online prescriptions in the hospital which stimulates the market of breast cancer with increased online pharmacies and increased connectivity help to grow the breast cancer market during the forecast period.
On the basis of geography, North America holds the highest position in the market with an increased market share in breast cancer. Advanced developed technologies in the market with an increased number of treatments available for treating breast cancer with an increasing number of patients helps to propel the market growth with increased government initiative in developing new drug developments and increased efficacy of the medications with increased results help to enhance the market growth.
Increased number of market players with increased investment for new developments and expansion of the breast cancer market size. Asia Pacific to be second highest market share with an increasing number of patients and demands. Europe, Latin America, the Middle East, and Africa are in the process to grow the market.
Segments Covered In The Report
By Therapy
By Cancer Type
By Distribution Channel
By Geography
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Breast Cancer Market
5.1. COVID-19 Landscape: Breast Cancer Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Breast Cancer Market, By Therapy
8.1. Breast Cancer Market, by Therapy, 2023-2032
8.1.1 Targeted Therapy
8.1.1.1. Market Revenue and Forecast (2021-2032)
8.1.2. Hormonal Therapy
8.1.2.1. Market Revenue and Forecast (2021-2032)
8.1.3. Surgery and radiation therapy
8.1.3.1. Market Revenue and Forecast (2021-2032)
8.1.4. Biologic therapy
8.1.4.1. Market Revenue and Forecast (2021-2032)
Chapter 9. Global Breast Cancer Market, By Cancer Type
9.1. Breast Cancer Market, by Cancer Type, 2023-2032
9.1.1. Hormone Receptor
9.1.1.1. Market Revenue and Forecast (2021-2032)
9.1.2. HER2+
9.1.2.1. Market Revenue and Forecast (2021-2032)
Chapter 10. Global Breast Cancer Market, By Distribution Channel
10.1. Breast Cancer Market, by Distribution Channel, 2023-2032
10.1.1. Hospital Pharmacies
10.1.1.1. Market Revenue and Forecast (2021-2032)
10.1.2. Retail Pharmacies
10.1.2.1. Market Revenue and Forecast (2021-2032)
10.1.3. Online Pharmacies
10.1.3.1. Market Revenue and Forecast (2021-2032)
10.1.4. Others
10.1.4.1. Market Revenue and Forecast (2021-2032)
Chapter 11. Global Breast Cancer Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Therapy (2021-2032)
11.1.2. Market Revenue and Forecast, by Cancer Type (2021-2032)
11.1.3. Market Revenue and Forecast, by Distribution Channel (2021-2032)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Therapy (2021-2032)
11.1.4.2. Market Revenue and Forecast, by Cancer Type (2021-2032)
11.1.4.3. Market Revenue and Forecast, by Distribution Channel (2021-2032)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Therapy (2021-2032)
11.1.5.2. Market Revenue and Forecast, by Cancer Type (2021-2032)
11.1.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2032)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Therapy (2021-2032)
11.2.2. Market Revenue and Forecast, by Cancer Type (2021-2032)
11.2.3. Market Revenue and Forecast, by Distribution Channel (2021-2032)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Therapy (2021-2032)
11.2.4.2. Market Revenue and Forecast, by Cancer Type (2021-2032)
11.2.4.3. Market Revenue and Forecast, by Distribution Channel (2021-2032)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Therapy (2021-2032)
11.2.5.2. Market Revenue and Forecast, by Cancer Type (2021-2032)
11.2.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2032)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Therapy (2021-2032)
11.2.6.2. Market Revenue and Forecast, by Cancer Type (2021-2032)
11.2.6.3. Market Revenue and Forecast, by Distribution Channel (2021-2032)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Therapy (2021-2032)
11.2.7.2. Market Revenue and Forecast, by Cancer Type (2021-2032)
11.2.7.3. Market Revenue and Forecast, by Distribution Channel (2021-2032)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Therapy (2021-2032)
11.3.2. Market Revenue and Forecast, by Cancer Type (2021-2032)
11.3.3. Market Revenue and Forecast, by Distribution Channel (2021-2032)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Therapy (2021-2032)
11.3.4.2. Market Revenue and Forecast, by Cancer Type (2021-2032)
11.3.4.3. Market Revenue and Forecast, by Distribution Channel (2021-2032)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Therapy (2021-2032)
11.3.5.2. Market Revenue and Forecast, by Cancer Type (2021-2032)
11.3.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2032)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Therapy (2021-2032)
11.3.6.2. Market Revenue and Forecast, by Cancer Type (2021-2032)
11.3.6.3. Market Revenue and Forecast, by Distribution Channel (2021-2032)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Therapy (2021-2032)
11.3.7.2. Market Revenue and Forecast, by Cancer Type (2021-2032)
11.3.7.3. Market Revenue and Forecast, by Distribution Channel (2021-2032)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Therapy (2021-2032)
11.4.2. Market Revenue and Forecast, by Cancer Type (2021-2032)
11.4.3. Market Revenue and Forecast, by Distribution Channel (2021-2032)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Therapy (2021-2032)
11.4.4.2. Market Revenue and Forecast, by Cancer Type (2021-2032)
11.4.4.3. Market Revenue and Forecast, by Distribution Channel (2021-2032)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Therapy (2021-2032)
11.4.5.2. Market Revenue and Forecast, by Cancer Type (2021-2032)
11.4.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2032)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Therapy (2021-2032)
11.4.6.2. Market Revenue and Forecast, by Cancer Type (2021-2032)
11.4.6.3. Market Revenue and Forecast, by Distribution Channel (2021-2032)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Therapy (2021-2032)
11.4.7.2. Market Revenue and Forecast, by Cancer Type (2021-2032)
11.4.7.3. Market Revenue and Forecast, by Distribution Channel (2021-2032)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Therapy (2021-2032)
11.5.2. Market Revenue and Forecast, by Cancer Type (2021-2032)
11.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2032)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Therapy (2021-2032)
11.5.4.2. Market Revenue and Forecast, by Cancer Type (2021-2032)
11.5.4.3. Market Revenue and Forecast, by Distribution Channel (2021-2032)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Therapy (2021-2032)
11.5.5.2. Market Revenue and Forecast, by Cancer Type (2021-2032)
11.5.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2032)
Chapter 12. Company Profiles
12.1. Merck & Co
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Bristol Myers Squiib
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Kyowa Kirin
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Eisai Co.Ltd
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Sanofi
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Pfizer Inc
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. AstraZeneca
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Novartis AG
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Eli Lilly and Company
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Genentech
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client